Medical Center Teodora EOOD

At Medical Center Teodora EOOD researchers are exploring innovative approaches to lower cardiovascular risk in patients with established disease or high‑risk profiles. Current studies focus on reducing major adverse cardiac events, preventing heart‑failure progression, and improving blood‑pressure control through novel lipid‑lowering agents and combination therapies.

• Inclisiran for LDL‑C reduction in atherosclerotic disease
• Zilebesiran targeting hypertension and cardiovascular outcomes
• Baxdrostat combined with dapagliflozin to prevent heart failure
• Evaluation of long‑term safety of RNA‑based therapies
• Assessment of cardiovascular event reduction in high‑risk cohorts

With 18 investigators leading 16 trials, the site contributes valuable data to European cardiovascular research networks.

The center’s immune‑focused program investigates targeted biologics for conditions such as Sjögren's disease and related autoimmune disorders. Trials aim to determine whether new antibodies can modulate disease activity and improve patient‑reported outcomes.

• Nipocalimab efficacy in moderate to severe Sjögren's disease
• Biomarker analysis for immune response modulation
• Safety profiling of novel monoclonal antibodies
• Comparative studies with placebo in autoimmune populations
• Exploration of patient‑centered quality‑of‑life measures

These investigations support the broader effort to expand therapeutic options for patients with systemic immune dysfunction.

In the musculoskeletal arena, Medical Center Teodora EOOD is conducting multiple studies on inflammatory arthritis, including rheumatoid arthritis and psoriatic arthritis. The trials evaluate new biologics, biosimilars, and oral agents to achieve better joint control and reduce disease progression.

• Bimekizumab versus risankizumab in active psoriatic arthritis
• Sonelokimab dosing strategies and long‑term safety
• MB04 biosimilar comparison with Enbrel® in rheumatoid arthritis
• AP1189 combined with methotrexate for early rheumatoid arthritis
• IMVT‑1402 assessment in ACPA‑positive rheumatoid arthritis

Across 16 studies, the site engages rheumatology experts to advance treatment paradigms for debilitating joint diseases.

A focused neurological trial at the center evaluates a novel compound for patients experiencing focal onset seizures. The objective is to assess seizure frequency reduction and overall safety compared with standard care.

• SPN‑817 efficacy in adult focal seizures
• Dose‑response analysis of the investigational agent
• Monitoring of adverse events and tolerability
• Impact on quality of life for seizure patients
• Integration of electroencephalogram biomarkers

The study adds to the limited pool of European data on emerging antiepileptic therapies.

Research on skin‑related connective disorders centers on improving outcomes for patients with psoriatic arthritis and related skin manifestations. Trials test next‑generation biologics to alleviate joint pain while also addressing skin lesions.

• Guselkumab efficacy in active psoriatic arthritis
• Comparative assessment of sonelokimab versus placebo and risankizumab
• Long‑term safety monitoring of biologic treatments
• Evaluation of patient‑reported skin symptom improvement
• Exploration of treatment‑naïve versus biologic‑experienced cohorts

The site’s multidisciplinary team bridges dermatology and rheumatology to deliver comprehensive care options.